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Abstract
Rationale Adjuvant cancer chemotherapy can cause long-
lasting, cognitive deficits. It is postulated that these
impairments are due to these drugs targeting neural
precursors within the adult hippocampus, the loss of which
has been associated with memory impairment.
Objectives The present study investigates the effects of the
chemotherapy, methotrexate (MTX) on spatial working
memory and the proliferation and survival of the neural
precursors involved in hippocampal neurogenesis, and the
possible neuroprotective properties of the antidepressant
fluoxetine.
Methods Male Lister hooded rats were administered MTX
(75 mg/kg, two i.v. doses a week apart) followed by
leucovorin rescue (i.p. 18 h after MTX at 6 mg/kg and at
26, 42 and 50 h at 3 mg/kg) and/or fluoxetine (10 mg/kg/
day in drinking water for 40 days). Memory was tested
using the novel location recognition (NLR) test. Using
markers, cell proliferation (Ki67) and survival (bromodeox-
yuridine/BrdU), in the dentate gyrus were quantified.
Results MTX-treated rats showed a cognitive deficit in the
NLR task compared with the vehicle and fluoxetine-treated
groups. Cognitive ability was restored in the group
receiving both MTX and fluoxetine. MTX reduced both
the number of proliferating cells in the SGZ and their
survival. This was prevented by the co-administration of
fluoxetine, which alone increased cell numbers.
Conclusions These results demonstrate that MTX induces
an impairment in spatial working memory and has a
negative long-term effect on hippocampal neurogenesis,
which is counteracted by the co-administration of fluox-
etine. If translatable to patients, this finding has the
potential to prevent the chemotherapy-induced cognitive
deficits experienced by many cancer survivors.
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Introduction
Many patients who have received adjuvant chemotherapy
to treat cancer have experienced cognitive deficits including
the reduced ability to form new memories, lack of
concentration and general confusion (Taillibert et al.
2007). These symptoms have been reported to persist for
several years after completion of the treatment (Ahles et al.
2002; Matsuda et al. 2005), affecting patient quality of life
and their ability to work (Ahles and Saykin 2001). The
cognitive effects of chemotherapy have been observed in
patients who have recovered from a range of cancers (Ahles
and Saykin 2001; Kaasa et al. 1988; Taillibert et al. 2007).
In studies of breast cancer survivors, most investigations
have found a mild to moderate effect on working, visual
and verbal memory (Falleti et al. 2005; Jansen et al. 2005;
Matsuda et al. 2005; Stewart et al. 2006). Neuroimaging
studies of patients showed that chemotherapy treatment
affects both grey and white matter volumes (Inagaki et al.
2007; Saykin et al. 2003; Stemmer et al. 1994) with
alterations in specific memory-associated areas of the brain,
including the hippocampus (Nakano et al. 2002).
Several previous studies have used rodent models to
investigate the effect of chemotherapy drugs on different
aspects of learning and memory (Fardell et al. 2010; Foley
et al. 2008; Gandal et al. 2008; Konat et al. 2008; MacLeod
et al. 2007; Mustafa et al. 2008; Seigers et al. 2007;
Winocur et al. 2006; Yang et al. 2010), all showing
chemotherapy-induced cognitive impairment. Furthermore,
some of these studies showed reduced hippocampal neuro-
genesis as a result of the chemotherapy (ElBeltagy et al. 2010;
Seigers et al. 2007; Yang et al. 2010). However, other studies
have found that chemotherapy does not affect memory (Foley
et al. 2008; MacLeod et al. 2007), or can even cause an
improvement (Lee et al. 2006). Comparable to human trials,
different drugs and dosing regimens are often used which may
explain these anomalies, but the consensus is that cognitive
impairment does occur following chemotherapy in both
patient and rodents (Hede 2008; Myers 2009).
The effects of cytotoxic drugs on hippocampal neuro-
genesis is a potential mechanism for the cognitive impair-
ments seen (ElBeltagy et al. 2010; Mustafa et al. 2008;
Seigers et al. 2007; Yang et al. 2010). The subgranular zone
(SGZ) of the dentate gyrus within the hippocampus is one
region of the brain where neurogenesis continues through-
out adulthood. The generation of new neurones which are
incorporated into the dentate gyrus is thought to have a
functional role in both memory consolidation and spatial
working memory, both functions of the hippocampal
formation (Ehninger and Kempermann 2008; Zhao et al.
2008).
Despite the increasing body of evidence for chemotherapy-
induced cognitive impairment, the mechanisms causing this
are still not understood and there have been few attempts to
counteract it. Fluoxetine is an SSRI antidepressant reported to
improve the memory deficits seen in patients with mild
cognitive impairment (Mowla et al. 2007), depression
(Gallassi et al. 2006; Levkovitz et al. 2002; Vythilingam et
al. 2004), post traumatic stress disorder (Vermetten et al.
2003) and traumatic brain injury (Horsfield et al. 2002).
These results are supported by rodent investigations showing
fluoxetine increases levels of brain-derived neurotrophic
factor (BDNF; Alme et al. 2007; Duman and Monteggia
2006), the rate of neurogenesis (Chen et al. 2006; Duman
2004; Marcussen et al. 2008) and the survival of new
neurones (Duman et al. 2001; Hitoshi et al. 2007) in the
hippocampus. All of these factors are thought to play a role
in memory consolidation (Kitabatake et al. 2007; Lledo et al.
2006; Zhao et al. 2008). While fluoxetine may not have any
beneficial effects on healthy subjects (Monleon et al. 2007),
a recent study found that it can improve cognition after 5-
fluorouracil chemotherapy in rats (ElBeltagy et al. 2010).
The present study investigates whether fluoxetine alters
cognitive deficits induced by methotrexate (MTX) chemo-
therapy in rats, and examines its effect on neurogenesis in
the hippocampus. MTX is an antimetabolite, commonly
used to treat several types of cancer including breast cancer
(Rousseau et al. 2000) and is often used in adjuvant
chemotherapy combinations which have been associated
with impaired cognition (Falleti et al. 2005; Matsuda et al.
2005). Used in high doses, it is co-administered with
leucovorin (LCV) to reduce its toxicity. MTX is an
inhibitor of tetrahydrofolate (THFA) reductase and THFA
is necessary for DNA synthesis. LCV is a THFA which
doesn't require THFA reductase, replenishing pools deplet-
ed by MTX (Genestier et al. 2000; Seigers et al. 2007). The
dose and protocol chosen in the present study is within the
range of clinical doses (Lobo and Balthasar 2002; Peters et
al. 1993), and has been used by Seigers et al. who found
them to significantly suppress hippocampal cell prolifera-
tion in the adult rat (Seigers et al. 2007). Moreover, the
fluoxetine was delivered orally to mimic clinical adminis-
tration and to prevent the stress of injection. The dose was
chosen from previous work in our laboratory which
counteracted memory deficits caused by the chemotherapy
agent 5-fluorouracil (ElBeltagy et al. 2010). Fluoxetine was
given for 40 days before, during and after MTX treatment
as it takes at least 21 days in rat to have anxiolytic effects
(Conley and Hutson 2007) and increase neurogenesis in the
hippocampus (Kodama et al. 2004). Spatial memory was
tested 6 days after the end of fluoxetine treatment, as it
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takes 3 days to wash out of the system (Caccia et al. 1990),
using the novel location recognition (NLR) test (Dix and
Aggleton 1999) and the drug's effects on both survival and
proliferation of new-born hippocampal neurones were
determined.
Materials and methods
Animals and treatment
Male Lister hooded rats (150–200 g; Charles River, UK)
were randomly allocated to vehicle (n=12), MTX/LCV (n=
12), fluoxetine (n=12) or MTX/LCV+fluoxetine (n=11)
groups. Animals were housed in cages of four and allowed
to habituate for 2 weeks prior to drug administration.
Rats in MTX/LCV groups were administered MTX
(75 mg/kg, two i.v. doses a week apart, at a volume of
0.5 ml/kg; Mayne Pharma Plc, UK) and rats in non-MTX/
LCV groups were given an identical volume of 0.9% sterile
saline (i.v.). LVC (CP Pharmaceuticals, UK; or saline for
non-MTX/LCV groups) was administered i.p. 18 h after
each MTX injection at 6 mg/kg and 26, 42 and 50 h after at
3 mg/kg (at a volume of 1 ml/kg). BrdU was administered
to all groups on the day of their first injection (250 mg/kg,
i.p., at a volume of 5 ml/kg; Sigma Aldrich, UK).
Mean water consumption and animal weight were moni-
tored throughout the experiment. Fluoxetine (Pinewood
Healthcare, Ireland, Oral solution) was administered in
drinking water at a dose of 10 mg/kg/day, estimated from
the water consumption and calculated on a daily basis.
Fluoxetine-treated drinking water was administered to ani-
mals in these groups for 40 days, starting a week prior to first
MTX injection.
MTX or saline equivalent was administered by i.v. injection
to the tail vein in 0.9% saline under isofluorane anaesthetic.
Injection courses began 3 weeks after animal arrival.
Throughout the experiment, rats were maintained with a 12-
h light/dark cycle (7.00/19.00 h) with ad libitum food and
water. Principles of laboratory animal care were in accordance
to UK Home Office Guidance regulations and with local
ethical committee approval.
Behavioural testing
Novel location recognition
The NLR test used here is a spatial variant of a two trial
object recognition task adapted from Dix and Aggleton
(Dix and Aggleton 1999; Fig. 1). The apparatus consisted
of an arena (a semi-transparent Perspex box, dimensions;
49-cm wide×66-cm long×40-cm high) and pink, weighted
water bottles (replicas, 15-cm high, 7-cm diameter). Arenas
and water bottles (objects) were cleaned with 20% ethanol
prior to each experiment and between trials to remove
olfactory cues. A black square of card was on the wall of
the room during trials to provide prominent cues for spatial
orientation. Experiments were conducted at an illumination
of 80 Lux between 0900 and 1400 hours.
Testing was carried out 6 days after fluoxetine treatment
ended. Rats were habituated to the arena for 30 min, 24 h
prior to testing (during which EthoVision 4.1 was used to
measure the mean velocity of the rats) and for 3 min, 5 min
before the familiarisation trial (King et al. 2004). During
the 3-min familiarisation trial, rats were placed in the arena
to explore two identical objects in separate corners. Rats
were returned to their home cage for 15 min and then
returned to the arena for the 3-min choice trial. In this trial,
one of the objects remained in the same place and one had
been moved to a new location and the rats were again left to
explore the two objects. The starting location of objects was
randomised. Exploration was defined as the rat directing its
nose in the direction of the object less than 1 cm from the
object, and actively exploring it (Dix and Aggleton 1999).
15mins
Familiarisation trial
3 mins
Choice trial
3 mins3 mins
1 min24 hrs
30 mins
Habituation 2Habituation 1
Fig. 1 The novel location recognition protocol was carried out over
2 days. Rats were habituated in the arena for 30 min and for a further
3 min 24 h later. They were then removed for 1 min whilst two
identical objects were placed in two corners of the arena. Rats were
replaced in the arena and allowed to explore the objects for 3 min
(familiarisation trial) then removed again for 15 min. When returned
again, one object had been moved to a different corner and rats were
again left to explore for 3 min (choice trial)
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Gnawing or climbing the object was not considered
exploration. Exploration times of both objects and trials
were recorded blind twice and averaged using a stopwatch
from digitised recordings, so no observer was in the room
during the trials.
Brain tissue preparation
The day after behavioural testing was completed rats were
put down by rapid stunning and cervical dislocation. Brains
were removed, cut sagittally and one half was cryopre-
served in 30% sucrose solution for 3 h at 4°C, then
embedded in OCT-compound (VWR International Ltd.,
UK) and snap frozen in liquid nitrogen-cooled isopentane.
Brains were stored at −80°C until being coronally sectioned
using a Leica CM 100 cryostat (Leica Microsystems, UK)
at 20-μm thickness at −20°C. The sections were thaw
mounted onto 3-aminopropylmethoxysaline-coated slides
and stored at −20°C until used for immunohistochemistry.
Immunohistochemistry
For both Ki67 and BrdU staining, a systematic random
sampling technique was used (Mayhew and Burton 1988).
Every 20th section throughout the entire length of the
dentate gyrus was selected, resulting in a total of nine to 11
sections per brain. All immunohistochemistry incubations
were carried out at room temperature in a light-proof
humidity chamber.
Ki67
All dilutions and washes (performed three times) were
carried out with phosphate-buffered saline (PBS). Sections
were fixed using 0.5% paraformaldehyde (PFA) for 3 min,
washed then incubated with monoclonal mouse anti-Ki67
primary antibody (1:300; Vector laboratories, UK) for 1 h,
followed by a further wash and 1-h incubation with Alexa
555 donkey anti-mouse (1:300; Invitrogen, UK). Sections
then had a final wash, were mounted with (diamidinophe-
nylindole) DAPI (1.5 μg/ml) nuclear marker (Vector
laboratories, UK) and coverslipped.
BrdU
All washes were performed three times with 0.1 M sodium
borate adjusted to pH 8.5 (borate buffer) unless otherwise
stated. Sections were fixed in 4% PFA for 3 min, washed,
then DNA was denatured by incubation in 2 M hydro-
chloric acid (HCl) containing 0.3% triton X-100 (Sigma
Aldrich, UK) for 20 min, immediately followed by 10-min
incubation with 5 M HCl. Sections were then washed and
neutralised for 12 min in the borate buffer then blocked
with 5% bovine serum albumin (BSA; Sigma Aldrich, UK)
in PBS containing 0.15% triton X-100 for 30 min. After
washing, sections were incubated for 16–20 h with
polyclonal sheep anti-BrdU primary antibody (1:100;
Abcam, UK) in the blocking solution, followed by washing
and incubation with Alexa 488 donkey anti-sheep second-
ary antibody (1:300; Invitrogen, UK) in PBS. Sections then
had a final wash in PBS, mounted with DAPI and
coverslipped.
All staining was viewed and quantified at ×40 on a
Nikon EFD-3 fluorescence microscope. BrdU- and Ki67-
positive cells which co-localised with the DAPI nuclear
staining within both blades of the dentate gyrus (or within a
3 cell diameter of the inner edge) were counted. By
combining cell counts per section for the whole dentate
gyrus and multiplying by 20, an estimate of total co-stained
cell numbers was produced (Huang and Herbert 2006). All
counting was performed blind.
Statistical analysis
Statistical analysis and graphs were created using GraphPad
Prism 4.0 and significance was regarded as p<0.05. Student's
paired t tests were used to compare exploration times of
animals in the familiarisation and choice trials. Preference
indices (PI) were created by expressing time spent exploring
the object in the novel location as a percentage of the sum of
exploration time of novel and familiar locations in the choice
trial, to create a single value to compare between groups
(Bruel-Jungerman et al. 2005). PI was compared to 50%
chance using a one-sample t test. One-way ANOVA was
used to compare PI, total exploration time and average
velocity of the animals and cells counts. Two-way repeated
measured ANOVAwas run to determine difference in animal
weight between treatment groups. When ANOVA was
significant Bonferonni post hoc test was performed.
Results
Methotrexate and fluoxetine reduce weight gain
A two-way repeated measure ANOVA revealed an effect of
group (F3,43=4.16, p<0.001, Supplementary Fig. 1a–b).
Rats treated with MTX/LCV, fluoxetine or both in
combination gained significantly less weight compared to
vehicle-treated controls and this change persisted to the end
of the study (p<0.001). This was attributed to disruption of
intestinal absorption caused by MTX (Carneiro-Filho et al.
2004) and fluoxetine (Freeman et al. 2006). A significant
effect of time and treatment×time interaction was also
confirmed (F56,2408=1793, F168,2408=4.93, respectively, p<
0.0001 for both).
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Fluoxetine prevents the spatial working memory deficits
caused by methotrexate
The NLR test was used to observe the effects of MTX/LCV
and fluoxetine on spatial working memory. None of the
treatment groups showed a significant difference in the
exploration time of the two objects in the familiarisation trial
(p>0.05, Fig. 2a), indicating no preference for the location of
either object. In the choice trial, Student's paired t tests
revealed that the vehicle and fluoxetine-treated groups
explored the object in a novel location to a significantly
greater extent (p<0.01, Fig. 2b), suggesting unaffected spatial
working memory (Dix and Aggleton 1999). In contrast the
MTX/LCV group showed no preference for either the novel
or familiar object, showing no significant difference between
exploration time for each object (p>0.05). This result
indicates that MTX treatment caused a deficit in spatial
working memory. Rats administered both MTX/LCV and
fluoxetine which showed a significant preference for the
object in the novel location (p<0.05) in the choice trial. This
group behaved similarly to control or fluoxetine-treated rats
and did not show the spatial memory deficit exhibited by the
MTX group. Unexpectedly, ANOVA revealed between
groups total exploration time for both trials (F3,43=13.29,
p<0.001). It was significantly higher for the fluoxetine group
compared to each other group (p<0.001). Further analysis
was carried out on exploration times within the choice trial by
conversion of raw data into a PI (Bruel-Jungerman et al.
2005; Fig. 2c). PI were created by expressing time spent
exploring the object in the novel location as a percentage of
the sum of exploration time of novel and familiar locations.
This showed the mean PI of the vehicle, fluoxetine and
MTX/LCV+fluoxetine groups were significantly differ-
ent from 50% chance (one-sample t test, p>0.05), while
the PI of the MTX group was not. Using the PI for
comparison between groups using ANOVA however,
showed no significant difference between treatment
groups (F3,43=1.85, p>0.05). No significant difference
between mean locomotor velocity (recorded during the
habituation period; (F3,43=2.70, p>0.05, Fig. 3) was
found between the groups indicating that different groups
were not impaired in their activity.
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Fig. 2 Mean exploratory times (mean±SEM) of the rats for each
object in the familiarisation (a) and choice (b) trial of the NLR task. In
the familiarisation trial, none of the groups spent a significantly
different time exploring either of the two objects (p>0.05). In the
choice trial, vehicle-treated, fluoxetine-treated and MTX/LCV admin-
istered with fluoxetine-treated rats spent significantly longer exploring
the object in the novel location compared with the familiar location
(single asterisk, p<0.05; double asterisk, p<0.01), whereas MTX/
LCV failed to discriminate (p>0.05). Compared to 50% chance, mean
(mean±SEM) preference indices (PI), of the vehicle, fluoxetine and
MTX/LCV+fluoxetine groups were significantly different (single
asterisk, p<0.05; double asterisk, p<0.01), whilst the MTX/LCV
group was not (c), however PI was not significantly different between
groups (p>0.05,). The total exploration time of familiarisation and
choice trial combined (d) was significantly higher for the fluoxetine
group compared to other groups (p<0.001)
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Fluoxetine prevents the reduction in cell proliferation
in the SGZ caused by methotrexate
Ki67 was used to quantify the numbers of dividing cells in
the SGZ of the dentate gyrus at the end of the experiment,
40 days after the final saline or LCV injection (Fig. 4). A
one-way ANOVA showed significant differences between
mean Ki67-positive cell counts (F3,24=11.58, p<0.001,
Fig. 4d). Further analysis with a Bonferroni post hoc test
revealed that rats treated only with MTX/LCV had a
significantly reduced number of Ki67-positive cells, having
48% (±3.9 SEM) of those found in saline-treated control
animals (p>0.05). In contrast, rats treated only with
fluoxetine had 37% (±4.5 SEM) more Ki67-positive cells
compared with the controls, a significant increase (p>0.05).
Rats treated with both MTX/LCVand fluoxetine showed no
significant difference in Ki67-positive cell numbers from
the vehicle-treated controls, indicating that the fluoxetine
had prevented the reduction in cell proliferation caused by
MTX/LCV.
Fluoxetine reverses reduction in new-born hippocampal cell
survival caused by methotrexate
BrdU was administered to rats on the first day of either
saline or MTX/LCV injections to label cells undergoing
division at the start of treatment. BrdU-positive cells were
quantified in the SGZ 48 days later to determine the
survival of these cells (Fig. 5). A one-way ANOVA showed
significant differences between mean Ki67-positive cell
counts (F3,20=24.34, p<0.001, Fig. 5d). Bonferroni post
hoc test revealed that MTX/LCV treatment significantly
reduced the number of BrdU-positive cells (p<0.001) by
66% (±6.4 SEM) compared to vehicle-treated controls
indicating that the chemotherapy, as well as reducing cell
proliferation was reducing the survival of cells dividing at
the start of treatment. Treatment with fluoxetine on its own
significantly increased BrdU-positive cell numbers by 44%
(±4.8 SEM; p<0.05). Animals co-treated with MTX/LCV
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Fig. 3 Mean velocity (mean±SEM) of rats (n=11–12) was not
significantly different between groups (in all cases p>0.05)
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Fig. 4 Photos showing positive immunostaining for proliferating cell
marker Ki67 (red; b), nuclear stain DAPI (blue; a) and photos merged
(c). Mean Ki67-positive cells counts (d; n=7) of the MTX/LCV-
treated group were significantly lower and fluoxetine-treated groups
significantly higher compared to the vehicle-treated group (single
asterisk, p<0.05). Bar scales indicate 20 μm
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and fluoxetine showed no significant difference in the
BrdU-positive cell numbers from vehicle-treated control
animals (p>0.05). These results suggest that fluoxetine can
protect newly dividing precursors in the dentate gyrus from
MTX-induced loss.
Discussion
The present study aimed to determine, firstly, the long-term
effects of MTX chemotherapy on spatial working memory
and its effects on cell proliferation and survival in the dentate
gyrus of the adult hippocampus. Secondly, we wished to see
whether the SSRI antidepressant, fluoxetine, could counteract
the behavioural and cellular effects ofMTX in a rodent model.
The NLR task was chosen to test spatial working memory,
firstly, as it is based upon rats' spontaneous preference
towards novelty as opposed to positive and negative
reinforcements which could confound results. Secondly, it
is hippocampal dependent (Mumby et al. 2002) and relies on
an intact dentate gyrus rather than other hippocampal
subregions to be successfully performed (Lee et al. 2005).
The SGZ of the dentate gyrus is one of the brain regions
where the formation of new neurons continues throughout
life (Ehninger and Kempermann 2008). Newly formed
dentate gyrus neurons have been shown to be preferentially
used in spatial learning tasks (Kee et al. 2007) and
reductions in dentate gyrus neurogenesis cause deficits in
the ability of animals to perform these tasks (Imayoshi et al.
2008). Over 80% of dividing cells in the SGZ are destined to
become dentate gyrus neurones (Snyder et al. 2009). It has
been suggested that chemotherapy may reduce hippocampal
neurogenesis and cause deficits in the cognitive domains
dependent upon this process (Dietrich et al. 2006; ElBeltagy
et al. 2010; Han et al. 2008; Mustafa et al. 2008; Seigers et
al. 2009). It has previously been assumed that systemic
chemotherapy could not cross the blood brain barrier and so
would have little effect on the brain. It has now been shown
that many chemotherapy agents, including MTX when
administered in high doses, can access the brain in
significant concentrations (Lassman et al. 2006).
In the present study, animals receiving a 2-week course
of MTX/LCV treatment were unable to recognise an object
in a novel location from an object in an old location in the
NLR behavioural test, 5 weeks after treatment had ended.
However animals treated with both MTX/LCV and fluox-
etine were able to distinguish the objects. This indicates
that MTX causes a decline in spatial working memory
compared to vehicle-treated controls or fluoxetine alone,
which is counteracted by the co-administration of fluox-
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Fig. 5 Immunostaining for BrdU (green; b) encorporated into DNA
48 days prior to rats death, nuclear stainer DAPI (blue; a) and photos
merged (c). Mean BrdU-positive cells counts (d; n=6) of the MTX/
LCV-treated group were significantly lower and fluoxetine-treated
groups significantly higher compared to the vehicle-treated group
(single asterisk, p<0.05; triple asterisk p<0.001). Bar scales indicate
20 μm
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etine. PI were formed from raw exploration data in the
choice trial to produce a single value for comparison
between groups. Although the PI of each group other than
MTX-treated animals significantly differed from chance, no
difference was found between groups, indicating that the
memory deficit seen is subtle. The data supports previous
reports that chemotherapy can cause spatial memory
deficits in both patients (Ahles and Saykin 2002; Matsuda
et al. 2005) and animals (ElBeltagy et al. 2010; Gandal et
al. 2008; Mustafa et al. 2008; Yang et al. 2010). In
particular, high doses of MTX have been shown to produce
spatial memory deficits in rats as measured in the Morris
water maze, novel object recognition and an instrumental
go/no-go tasks (Fardell et al. 2010; Seigers et al. 2007;
Seigers et al. 2009). Furthermore, Fardell et al. (2010)
demonstrated that these effects were both short and long
term, remaining 8 months after treatment, suggesting that
MTX has a lasting effect on the stem niche. The present
work is consistent with these findings and in addition
shows that lower doses are able to produce significant
impairments in the NLR test 5 weeks after termination of
the treatment. These results are comparable to clinical
observations of breast cancer sufferers showing memory
deficits after chemotherapy (Matsuda et al. 2005). Most
patient studies which have detected cognitive effects of
chemotherapy have looked at breast cancer survivors who
have received a combination of chemotherapy agents
including MTX (Brezden et al. 2000; Wieneke and Dienst
1995). LCV, used here as a recovery drug for the toxic effects
of MTX, has been shown to have subtle cognitive benefits in
aged rats with a folate deficiency in the hippocampal-
dependant T-maze task, but not in psychomotor and motor
activity and Morris water maze spatial learning tasks.
However LCV is thought not to have a cognitive effect on
rats with sufficient folate (Lalonde et al. 1993) and Seigers et
al. (2009) found it had no effect on neurogenesis when used
alone. This allows us to attribute the deficits in memory and
neurogenesis seen in the present study to the MTX
chemotherapy. Moreover, it is possible that LCV had a
positive cognitive effect when co-administered with the
MTX, and without it, the memory deficits seen in MTX-
treated animals may have been greater.
As spatial learning is thought to depend on both the
production and the survival of new-born neurones in the
dentate gyrus (Dupret et al. 2007), the effect of MTX on
both were investigated. In the present study, MTX/LCV
reduced the number of dividing cells in the SGZ of the
dentate gyrus, 40 days after the final injection compared to
the control group. Survival of cells dividing at the time of
the first MTX/LCV injection was also severely reduced.
These results suggest that MTX is reducing neurogenesis
and provide a mechanism for the cognitive effects produced
by this chemotherapy drug.
Fluoxetine is known to improve memory in patients with
impaired cognition (Gallassi et al. 2006; Levkovitz et al.
2002; Mowla et al. 2007) and to increase the number of
neurons produced during adult neurogenesis in the rodent
hippocampus (Kodama et al. 2004; Marcussen et al. 2008).
For these reasons, co-administration of fluoxetine with MTX
was tested to see if it could prevent the changes produced by
chemotherapy. The results show that both the behavioural
and cellular deficits were prevented when fluoxetine was
given for 40 days. Fluoxetine alone had no effect on PI, or
average velocity, but increased total exploration time of
animals. We have previously shown that fluoxetine can
prevent the cognitive deficits produced by 5-fluoruracil
(ElBeltagy et al. 2010) while the present study is the first
to demonstrate a reversal of the cognitive deficit induced by
MTX suggesting that fluoxetine may be able to prevent the
cognitive deficits induced by a range of chemotherapy drugs.
The mechanism by which fluoxetine is having these effects
is unclear. Fluoxetine may have little effect on cognition or
neurogenesis in healthy animals (Huang et al. 2008;
Monleon et al. 2007), but has been shown to be neuro-
protective after injury (Chiou et al. 2006; Jin et al. 2009) and
to up-regulate hippocampal neurogenesis when it is reduced
(Duman 2004; Duman et al. 2001; Feldmann et al. 2007).
Interestingly, unlike the results shown in the present study,
we previously found that fluoxetine did not increase
proliferation of cells within the dentate gyrus when
administered without chemotherapy (ElBeltagy et al. 2010).
This could be attributed to the increased length of time
animals received the antidepressant, from 21 days in the
previous study to 40 days in the present, highlighting the
importance of the period of time for which fluoxetine is
administered. In addition, fluoxetine has been reported to
increase levels of BDNF (Alme et al. 2007; Duman and
Monteggia 2006), a neurotrophic factor which regulates
neurogenesis (Alme et al. 2007; Duman et al. 2001). Further
investigations to quantify levels of BDNF within the
hippocampus may help to understand the pathways by
which fluoxetine acts in these situations.
If the effects of the fluoxetine demonstrated in the
present study can be translated to patients, it could provide
a relatively simple means to alleviate the cognitive effects
experienced by some cancer survivors. Further work is
needed in both animals and humans to determine the
effects of different chemotherapy agents and to examine
the impact of other antidepressants. As it has been shown
that MTX still affects cell proliferation in the hippocam-
pus after treatment has terminated, experiments investi-
gating the time course of when it would be beneficial to
administer antidepressants could generate some interesting
results.
In conclusion, this study reveals MTX chemotherapy
causes cognitive impairments and a reduction in both the
112 Psychopharmacology (2011) 215:105–115
proliferation and survival of neural precursors in the
hippocampus. Furthermore, these impairments were re-
versed by the co-administration of the SSRI antidepressant,
fluoxetine, suggesting it to have a neuroprotective effect.
This finding not only has potential to improve the quality of
life for cancer survivors, but provides further information
on chemotherapy-induced cognitive deficits and methods to
counteract it.
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